{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:46Z","timestamp":1792787746535,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Foundation for Rheumatology"},{"name":"Catalan Society of Rheumatology","id":[{"id":"https:\/\/ror.org\/03sgp5m15","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014165","name":"PHARMAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.rdc.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T08:25:21Z","timestamp":1599639921000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Gender and Ethnic Inequities in Gout Burden and Management"],"prefix":"10.1016","volume":"46","author":[{"given":"Andrea Garcia","family":"Guill\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Te Karu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2020.07.008_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(62)90501-9","article-title":"Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals","volume":"280","author":"Faires","year":"1962","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.rdc.2020.07.008_bib2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","article-title":"Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans","volume":"67","author":"Singh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2020.07.008_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","article-title":"The impact of gout on work absence and productivity","volume":"10","author":"Kleinman","year":"2007","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2020.07.008_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2020.07.008_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","article-title":"Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout","volume":"37","author":"Yue","year":"1964","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.rdc.2020.07.008_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2020.07.008_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.rdc.2020.07.008_bib10","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard.2006.051649","article-title":"Sex differences in gout epidemiology: evaluation and treatment","volume":"65","author":"Harrold","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.20680","article-title":"Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol","volume":"64","author":"Chohan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12891-017-1465-9","article-title":"Sex differences in gout characteristics: tailoring care for women and men","volume":"18","author":"Harrold","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib13","doi-asserted-by":"crossref","first-page":"R132","DOI":"10.1186\/ar4589","article-title":"The impact of gout on patient's lives: a study of African-American and caucasian men and women with gout","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2020.07.008_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12905-015-0277-z","article-title":"Why me? I don't fit the mould ... I am a freak of nature\": a qualitative study of women's experience of gout","volume":"15","author":"Richardson","year":"2015","journal-title":"BMC Womens Health"},{"issue":"9","key":"10.1016\/j.rdc.2020.07.008_bib15","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kew356","article-title":"Racial differences in health-related quality of life and functional ability in patients with gout","volume":"56","author":"Singh","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2020.07.008_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2474-13-15","article-title":"African American patients with gout: efficacy and safety of febuxostat vs allopurinol","volume":"13","author":"Wells","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib18","first-page":"498","article-title":"Gout in ambulatory care settings in the United States","volume":"35","author":"Krishnan","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2020.07.008_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3899\/jrheum.190522","article-title":"Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US veterans administration gout cohort","volume":"47","author":"Singh","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib21","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2020.07.008_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/23.4.276","article-title":"Hyperuricaemia, gout and kidney function in New Zealand Maori men","volume":"23","author":"Gibson","year":"1984","journal-title":"Br J Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2020.07.008_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/rheumatology\/33.10.932","article-title":"Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling","volume":"33","author":"Simmonds","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"1485","key":"10.1016\/j.rdc.2020.07.008_bib24","first-page":"8","article-title":"Gout in Aotearoa New Zealand: the equity crisis continues in plain sight","volume":"131","author":"Dalbeth","year":"2018","journal-title":"N\u00a0Z Med J"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10067-012-2110-5","article-title":"The experience and impact of gout in Maori and Pacific people: a prospective observational study","volume":"32","author":"Dalbeth","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2020.07.008_bib26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/art.40110","article-title":"Population-specific resequencing associates the ATP-binding cassette subfamily C member 4 gene with gout in New Zealand Maori and Pacific men","volume":"69","author":"Tanner","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2014-205877","article-title":"Twenty-eight loci that influence serum urate levels: analysis of association with gout","volume":"75","author":"Phipps-Green","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1429","key":"10.1016\/j.rdc.2020.07.008_bib28","first-page":"10","article-title":"Gout in Aotearoa New Zealand: are we going to ignore this for another 3 years?","volume":"129","author":"Dalbeth","year":"2016","journal-title":"N\u00a0Z Med J"},{"issue":"1404","key":"10.1016\/j.rdc.2020.07.008_bib29","first-page":"37","article-title":"Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers","volume":"127","author":"Jackson","year":"2014","journal-title":"N\u00a0Z Med J"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","article-title":"The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach","volume":"17","author":"Lindsay","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib31","first-page":"214","article-title":"Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study","volume":"5","author":"Te Karu","year":"2013","journal-title":"J\u00a0Prim Health Care"},{"key":"10.1016\/j.rdc.2020.07.008_bib32","series-title":"Equity of health care for M\u0101ori: a framework","year":"2014"},{"issue":"11","key":"10.1016\/j.rdc.2020.07.008_bib33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/acr.22879","article-title":"\"You don't have to be a drinker to get gout, but it helps\": a content analysis of the depiction of gout in popular newspapers","volume":"68","author":"Duyck","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib34","first-page":"149","article-title":"A\u00a0qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management","volume":"8","author":"Humphrey","year":"2016","journal-title":"J\u00a0Prim Health Care"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/acr2.11095","article-title":"Internalized and anticipated stigmatization in patients with gout","volume":"2","author":"Kleinstauber","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib37","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(19)30004-9","article-title":"Making the right thing the easy thing to do: strategies to improve outcomes in gout","volume":"1","author":"Dalbeth","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2020.07.008_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.31128\/AJGP-04-19-4909","article-title":"The challenges of managing gout in primary care: results of a best-practice audit","volume":"48","author":"Stamp","year":"2019","journal-title":"Aust J Gen Pract"},{"issue":"11","key":"10.1016\/j.rdc.2020.07.008_bib39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/acr.23544","article-title":"Improved gout outcomes in primary care using a novel disease management program: a pilot study","volume":"70","author":"Bulbin","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjquality.u210130.w4918","article-title":"Gout in primary care: can we improve patient outcomes?","volume":"6","author":"Callear","year":"2017","journal-title":"BMJ Qual Improv Rep"},{"issue":"10156","key":"10.1016\/j.rdc.2020.07.008_bib41","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rdc.2020.07.008_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.semarthrit.2016.10.006","article-title":"Pilot study of a multidisciplinary gout patient education and monitoring program","volume":"46","author":"Fields","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/15-234","article-title":"A\u00a0pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial","volume":"20","author":"Goldfien","year":"2016","journal-title":"Perm J"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib45","doi-asserted-by":"crossref","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.rdc.2020.07.008_bib46","first-page":"194","article-title":"Improving gout education from patients' perspectives: a focus group study of Maori and Pakeha people with gout","volume":"10","author":"Rolston","year":"2018","journal-title":"J\u00a0Prim Health Care"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib47","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/acr.23272","article-title":"Education preferences of people with gout: exploring differences between indigenous and nonindigenous peoples from rural and urban locations","volume":"70","author":"Treharne","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib48","first-page":"117","article-title":"Facilitating equitable prevention and management of gout for M\u0101ori in Northland, New Zealand, through a collaborative primary care approach","volume":"11","author":"Lawrence","year":"2019","journal-title":"J\u00a0Prim Health Care"},{"key":"10.1016\/j.rdc.2020.07.008_bib49","doi-asserted-by":"crossref","first-page":"l251","DOI":"10.1136\/bmj.l251","article-title":"Social determinants and non-communicable diseases: time for integrated action","volume":"364","author":"Marmot","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12939-019-1082-3","article-title":"Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition","volume":"18","author":"Curtis","year":"2019","journal-title":"Int J Equity Health"},{"issue":"23","key":"10.1016\/j.rdc.2020.07.008_bib51","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2020.07.008_bib52","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2020.07.008_bib53","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2020.07.008_bib54","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2020.07.008_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rdc.2020.07.008_bib56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2020.07.008_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2020.07.008_bib58","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2020.07.008_bib59","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6\u00a0month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:52Z","timestamp":1760181532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X20300806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0889857X20300806"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2020.07.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gender and Ethnic Inequities in Gout Burden and Management","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}